You're right, the industry has gone through some changes in recent months, and jobs have been lost.
But there is another point I would like to get across. We believe in Canada's and Quebec's potential. We want to invest more and we want to do that in Canada. Even though we have seen job losses, we have also seen investments being made in Quebec.
I would like to draw your attention to an initiative announced by Eli Lilly. The company is partnering with Teralys Capital to set up a new investment model in Quebec, which will really target the early stages of drug development.
I would also point to Roche Canada's designation of the Montreal Heart Institute as its hub for translational medicine studying cardiometabolic disease. That represents a major investment.
As you mentioned, we can make changes. Numerous factors are at play. We believe the government could make strategic changes to improve the country's intellectual property regime and its ability to attract researchers. That means improvements to the right of appeal, data protection and patent restoration. Such measures could enhance Canada's ability to compete for investments.